)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Adaptimmune Therapeutics (ADAP) investor relations material
Adaptimmune Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary13 Aug, 2025
Executive summary
Revenue for the quarter ended June 30, 2025, was $13.7 million, down 89% year-over-year, primarily due to the end of the Genentech collaboration; product revenue from TECELRA increased following FDA approval in August 2024, with Q2 sales reaching $11.1 million and over 150% growth versus Q1 2025.
Net loss for the quarter was $30.3 million, compared to net income of $69.5 million in the same quarter last year; net loss for the six months was $77.9 million.
Major restructuring and asset sale to US WorldMeds completed in July 2025, including a $55 million upfront payment and up to $30 million in future milestone payments.
Workforce reduction of approximately 62% announced post-transaction, with $7–8 million in expected severance costs.
Debt repaid and restructuring underway to focus on PRAME and CD70 T-cell therapy assets.
Financial highlights
Total revenue for the six months ended June 30, 2025, was $21.0 million, down 84% year-over-year.
Product revenue for the quarter was $11.1 million, up from $0 in the prior year, reflecting TECELRA commercialization.
Operating expenses for the quarter were $44.0 million, down 26% year-over-year, driven by lower R&D and SG&A costs.
Cash and cash equivalents at June 30, 2025, were $26.1 million, down from $91.1 million at year-end 2024.
Net cash used in operating activities for the six months was $101.4 million.
Outlook and guidance
Management expects current liquidity, combined with proceeds from the asset sale, to fund operations for at least 12 months.
Focus will shift to monetizing remaining preclinical assets and potential future financing activities.
Lete-cel launch planned for 2026 under US WorldMeds.
Explain rationale for restructuring post-TECELRA sale.
What is the status of lete-cel's planned 2026 launch?
What is driving the decrease in R&D expenses?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Adaptimmune Therapeutics earnings date
Q3 202512 Nov, 2025
Next Adaptimmune Therapeutics earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cell therapies for cancer patients, particularly those with solid tumors. The company utilizes a proprietary cell therapy platform to engineer a patient's own cells to target and fight cancer. Adaptimmune is involved in several phase II clinical trials, including SPEARHEAD-1 for synovial sarcoma and SURPASS-3 for platinum-resistant ovarian cancer. Their research and development efforts are supported by strategic collaborations with entities like Genentech, Inc. and F. Hoffman-La Roche Ltd, among others, to further the development and potential commercialization of their therapies. The company is headquartered in Abingdon, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage